Rapamycin
Rapamycin (Sirolimus) for Longevity
An mTOR inhibitor originally used in organ transplant patients, now emerging as the most evidence-backed pharmacological longevity intervention. The landmark Harrison 2009 study showed lifespan extension in mice, and the PEARL trial (2025) confirmed safety in healthy adults at longevity doses.
Key Research
Peer-Reviewed Evidence • 4 Citations
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison DE et al.•Nature•2009•PMID: 19587680
Key Finding: First demonstration that a drug can extend mammalian lifespan. +14% for females, +9% for males at 3 independent NIA ITP sites.
View on PubMedmTOR inhibition improves immune function in the elderly
Mannick JB et al.•Sci Transl Med•2014•PMID: 25540326
Key Finding: RAD001 enhanced influenza vaccine response by ~20% in elderly volunteers and reduced PD-1 exhaustion markers.
View on PubMedTORC1 inhibition enhances immune function and reduces infections in the elderly
Mannick JB et al.•Sci Transl Med•2018•PMID: 29997249
Key Finding: Phase 2a RCT: 6 weeks of TORC1 inhibition significantly decreased infection rates for a full year (P=0.001).
View on PubMedInfluence of rapamycin on safety and healthspan metrics after one year: PEARL trial
Moel M et al.•Aging•2025•PMID: 40188830
Key Finding: First year-long RCT of rapamycin in healthy adults. Safety equal to placebo. Women on 10mg/week showed improved lean mass and pain.
View on PubMedCitations sourced from PubMed, Cochrane Library, and peer-reviewed journals. Study findings are summarized for accessibility. Always consult the original publication for full methodology and results.
📊 Evidence by Outcome
9-14% lifespan extension in genetically diverse mice (Harrison 2009 Nature). Replicated at 3 NIA ITP sites. Strongest animal longevity drug data of any compound.
20 studies • Consistency: High • Effect: Large
Two RCTs (Mannick 2014, 2018) showed ~20% improved vaccine response and significantly reduced infection rates for 12 months after 6 weeks of low-dose treatment.
5 studies • Consistency: High • Effect: Moderate
Chung et al. 2019 RCT showed topical rapamycin reduced senescence markers (p16INK4A) and increased collagen VII in human skin. Promising but small sample.
2 studies • Consistency: Moderate • Effect: Moderate
👥 Community Insights
Been on 5mg weekly for a year. Labs look great, immune function improved. Longevity physician monitors closely.
Community member • USA• Verified
📋 Protocol Snapshot
Protocols are for informational purposes only. Always consult a qualified healthcare provider before starting any treatment protocol.
Where to Get It (UAE)
Browse all wellness centers →Related Treatments
Medical Disclaimer: The information on this page is for educational purposes only and is not intended as medical advice. Kamura Scores reflect a combination of research evidence, community data, and other factors — they are not clinical recommendations. Research citations are provided for reference; always consult the original publications for complete study details. Consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Individual results may vary.